STOUGHTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 25th Annual Needham Virtual Healthcare Conference Fireside Chat Date and Time: Wednesday, April 15, 2026, at 2:15 p.m.

6,224 shares were sold for a transaction value of ~$228,000 on March 9, 2026. This sale represented 6.40% of Dieter David's direct holdings prior to the transaction.

electroCore (NASDAQ: ECOR - Get Free Report) and Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Volatility and Risk electroCore has a beta of

Scott Dreyer sold 49,976 shares on March 3, 2026, for approximately $2.02 million at a weighted average price of about $40.41 per share. The sale reduced Dreyer's direct holdings by 41.05%, from 121,746 shares to 71,770 shares.

Collegium Pharmaceutical (NASDAQ: COLL) outlined plans to acquire the ADHD drug AZSTARYS and related corporate subsidiaries from Corium Therapeutics, a transaction the company said would add a second commercial-stage ADHD product alongside Jornay PM and extend the durability of its ADHD revenue base. Transaction terms and timing On the investor call, President and CEO Vikram Karnani

Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript

– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS Expected to Generate Over $50 Million in Second Half 2026 Pro Forma Net Revenue – – Expected Patent Protection into 2037 – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Acquisition to Be Funded by Collegium's Cash on Hand and Previously Announced $300 Million Delayed Draw Term Loan – – Conference Call Scheduled for Today at 9:00 a.m. ET – STOUGHTON, Mass.

Collegium Pharmaceutical (NASDAQ: COLL) highlighted a "record-breaking" 2025 and outlined its 2026 outlook at the Barclays Miami Conference, emphasizing strong performance from newly acquired ADHD product JORNAY PM alongside what management described as a durable pain portfolio. Management recaps a record 2025 CEO Vikram Karnani said 2025 delivered record net revenues and record adjusted EBITDA, alongside

Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain medications at PainConnect 2026, the American Academy of Pain Medicine (AAPM)'s Annual Meeting, taking place in Salt Lake City, Utah from March 5-8, 2026. The presentations highlight real-world clinical insights from Collegium's pain portfolio and reflect the Company's continued focus on generating evidence that helps inform everyday practice.